NDAINTRAVENOUSPOWDER
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
KIMYRSA (oritavancin diphosphate) by CorMedix is 12. Approved for skin structure infections (absssi) caused by susceptible isolates of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-susceptible, methicillin-resistant isolates), streptococcus pyogenes and 3 more indications. First approved in 2021.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KIMYRSA (oritavancin diphosphate) is an intravenous lipoglycopeptide antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI) caused by gram-positive organisms including MRSA, S. pyogenes, and S. agalactiae. It works by inhibiting bacterial cell wall synthesis with a single 1,200 mg IV dose achieving sustained tissue penetration via extensive protein binding and distribution. The drug's antimicrobial activity correlates with AUC/MIC ratio, supporting once-only dosing for appropriate infections.
$0.001BPart D
Peak8.9 years to LOEKIMYRSA is in peak commercial phase with modest initial adoption (198 Part D claims in 2023); brand team is likely executing market expansion and specialty care penetration strategies with stable staffing.
Mechanism of Action
12.1 Mechanism of Action Oritavancin is an antibacterial drug [see ] . 12.2 Pharmacodynamics The antimicrobial activity of oritavancin appears to correlate with the ratio of area under the concentration-time curve to minimal inhibitory concentration (AUC/MIC) based on animal models of infection.…
Worked on KIMYRSA at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.